Cancer Biostatistics (CB)

癌症生物统计学共享资源 摘要 癌症生物统计学共享资源（CB）提供最先进的生物统计学和研究设计， 支持亨斯迈癌症研究所的临床、转化、实验室和人口科学研究人员 （HCI）。CB为研究人员提供专家咨询，从制定研究目标到研究设计， 分析、开发新方法、解释和传播结果。CB包括9个 具有专门癌症专业知识的统计学家，针对癌症中心成员的当前和预期未来 需求，包括临床试验设计，癌症流行病学，因果推理，纵向数据分析， 预测建模、荟萃分析和贝叶斯技术。CB对成功做出了重大贡献， HCI的研究计划和进展，通过确保及时，严格， 在设计、分析和解释研究数据时使用适当的统计方法。年成立 1996年，CB由Kenneth Boucher博士和Benjamin Haaland博士执导。资源的目标是： 1)为HCI临床，翻译，实验室， 和人口科学研究人员;和2）支持癌症中心的科学研究目标 通过将生物统计方法应用于团队科学赠款，高影响力研究和临床试验， 质量，成本效益的方式。所有HCI研究人员都可以平等地获得CB。 CB通过确保严格的研究设计，准确， 可重复的、透明的数据分析和有效的结果。在当前的融资期内，CB贡献了 >140篇出版物和39项资助赠款，包括两项U 01，一项U 54，一项以患者为中心的成果 研究所（PCRI）赠款，和突破资助奖。CB目前参与的活动超过 26项HCI制药商发起的临床试验（IIT），并参与了117项研究的设计或分析 自2014年以来的临床试验。CB成员积极参与广泛的项目， 与我们的集水区特别相关，包括农村/边境癌症差异、治疗和预防 以及肺癌的护理标准。 CB通过固化研究问题增加了HCI研究的价值;改善了研究设计，行为和权力; 并利用严格的、可重复的和高质量的统计技术。CB与其他HCI密切合作 共享资源，以确保多资源项目中的最佳统计实践。同样，CB与 与HCI临床试验办公室合作，确保在设计、监测和分析中使用适当的方法 的HCI IIT。HCI的全部使命都受到了CB的影响，从了解癌症的起源，到 创造和改进癌症治疗，了解癌症风险，预防和护理。

CANCER BIOSTATISTICS SHARED RESOURCE ABSTRACT The Cancer Biostatistics Shared Resource (CB) provides state-of-the-art biostatistics and research design to support clinical, translational, laboratory, and population sciences investigators at Huntsman Cancer Institute (HCI). CB provides expert consulting for researchers, from formulation of research objectives to study design, analysis, development of novel methods, interpretation, and dissemination of results. CB includes nine statisticians with specialized cancer expertise targeting Cancer Center members’ current and anticipated future needs, including clinical trial design, cancer epidemiology, causal inference, longitudinal data analysis, predictive modeling, meta-analysis, and Bayesian techniques. CB contributes significantly to the success of HCI’s Research Programs and progress toward HCI’s strategic objectives by ensuring timely, rigorous, and appropriate statistical methods are used in design, analysis, and interpretation of research data. Established in 1996, CB is directed by Kenneth Boucher, PhD, and Benjamin Haaland, PhD. The aims of the Resource are: 1) to provide state-of-the-art biostatistics and research design support to HCI clinical, translational, laboratory, and population sciences investigators; and 2) to support the scientific research objectives of the Cancer Center by applying biostatistical methods for team science grants, high-impact research, and clinical trials in a high- quality, cost-effective manner. Access to CB is afforded equally to all HCI researchers. CB enhances scientific interactions and productivity at HCI by ensuring rigorous study design, accurate, reproducible, and transparent data analysis, and valid results. In the current funding period, CB has contributed to >140 publications and 39 funded grants, including two U01s, a U54, a Patient-Centered Outcomes Research Institute (PCORI) grant, and a Breakthrough Funding Award. CB currently participates in more than 26 HCI investigator-initiated clinical trials (IITs) and has been involved in the design or analysis of 117 proposed clinical trials since 2014. CB members are actively involved in a broad spectrum of projects of particular relevance to our catchment area, including rural/frontier cancer disparities, treatment and prevention of melanoma, and care standards for lung cancer. CB adds value to HCI research by solidifying research questions; improving study design, conduct, and power; and utilizing rigorous, reproducible, and high-quality statistical techniques. CB works closely with other HCI Shared Resources to ensure best statistical practices in multi-resource projects. Similarly, CB works closely with the HCI Clinical Trials Office to ensure appropriate methods are used in design, monitoring, and analysis of HCI IITs. The full spectrum of HCI’s mission is impacted by CB, from understanding cancer’s beginnings, to creation and improvement of cancer treatments, to understanding cancer risk, prevention, and care.